Abstract
Purpose: Adjuvant vaginal cuff brachytherapy (VBT) provides excellent local control in patients with early stage endometrial cancer (EC). VBT delivers a conformal dose to the vagina with less dose to surrounding normal tissues compared to external beam radiotherapy. Due to the low toxicity reported in EC patients treated with VBT alone, to our knowledge, there are no dose constraints to the organs at risk described in the literature. We purpose to evaluate toxicity of exclusive VBT in EC patients and to assess its relation with dosimetric parameters.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
